GLPwatch

[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].

Rev Med Liege · 2019

Last updated 2026-05-28

Semaglutide (Ozempic®) is a once-weekly injection for type 2 diabetes that helps lower blood sugar and aids weight loss. In clinical trials, doses of 0.5 mg or 1.0 mg once weekly were more effective at improving blood sugar control and reducing weight than other similar medications. It is given as a prefilled pen for self-injection and is reimbursed in Belgium for patients with a BMI of 30 or higher who have not responded to other diabetes treatments.

AI summary of the abstract below.

JournalRev Med Liege, 2019
Citations2
Relative citation ratio0.06
NIH percentile5
Molecules semaglutide
Conditions studied Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease

Abstract

Semaglutide (Ozempic®) is a new once-weekly agonist of glucagon-like peptide-1 receptors (GLP-1 AR) indicated in the treatment of type 2 diabetes (T2D). Phase III clinical trials of the SUSTAIN programme demonstrated both the efficacy and safety of semaglutide in patients with T2D treated by diet and exercise, oral antidiabetic agents or even insulin. Direct and indirect comparative clinical trials showed that semaglutide (subcutaneous 0.5 or 1.0 mg once weekly) exerts a better glucose-lowering activity and a greater weight loss than other GLP-1 AR. Presented as prefilled pens for subcutaneous injection, semaglutide is currently reimbursed in Belgium after failure of antidiabetic therapy including metformin (HbA1c superior to 7,5 % or 58 mmol/mol) in T2D patients with body mass index ? 30 kg/m².

Verbatim abstract via PubMed 31486321 ↗

Related research